Trial Radar AI | ||
|---|---|---|
Clinical Trial NCT03860857 (BEACoN) for Alzheimer Disease, Cognitive Impairment, Cognitive Decline is recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here. | ||
One trial matched filter criteria
Card View
Back to Search
University of California, IrvineBiomarker Exploration in Aging, Cognition and Neurodegeneration (BEACoN)
Clinical Trial NCT03860857 (BEACoN) is designed to study Health Services Research for Alzheimer Disease, Cognitive Impairment, Cognitive Decline. It is a Phase 3 interventional trial that is recruiting, having started on May 1, 2018, with plans to enroll 300 participants. Led by University of California, Irvine, it is expected to complete by December 22, 2027. The latest data from ClinicalTrials.gov was last updated on November 1, 2024.
Brief Summary
The purpose of this research study is to understand the factors that underlie changes in thinking and memory with increasing age. The investigators will test the usefulness of MRI, PET, and cognitive testing in detecting subtle changes in the brain that precede cognitive decline. An addendum to this study includes additional PET scans to examine the relationship between tau protein in the brain and cognitive decline. Tau is a protein that is known to form tangles in the areas of the brain important for memory, and these tau tangles are a hallmark of Alzheimer's disease. This sub-study research aims to look at the tau accumulation in the brain using an investigational drug called MK-6240, which is a radio tracer that gets injected prior to a positron emission tomography (PET) scan.
Detailed Description
This study investigates the relationship between Alzheimer's disease (AD) pathology, brain structure and function, as well as cognition in non-demented older adults. The goal is to develop a more complete understanding of the factors that lead to cognitive decline in the elderly and progression to AD. The investigators will enroll 200 cognitively intact adults between the ages of 60-85 years old from the UCI Alzheimer's Disease Research Center or directly from the local community. Study procedures will include: 1) PET amyloid scans with Amyvid™ radiotracer (florbetapir-F18) and PET tau scans with [18F]MK6240 radiotracer; 2) High-resolution structural, functional, and diffusion MRI; and 3) Cognitive examinations. The investigators will track cognitive outcomes through longitudinal monitoring. Amyloid imaging will only be conducted once in the study at baseline, and MRI and tau PET imaging will be at baseline and Year 1. The investigators aim to identify the best combination of tests for predicting longitudinal cognitive/clinical decline. The proposed study will significantly inform the understanding of cognitive decline in the aging brain and allow investigators to better define preclinical AD and make recommendations for future intervention trials.
Official Title
The BEACoN Study- Biomarker Exploration in Aging, Cognition and Neurodegeneration
Conditions
Alzheimer DiseaseCognitive ImpairmentCognitive DeclinePublications
Scientific articles and research papers published about this clinical trial:- Stevenson RF, Reagh ZM, Chun AP, Murray EA, Yassa MA. Pattern Separation and Source Memory Engage Distinct Hippocampal and Neocortical Regions during Retrieval. J Neurosci. 2020 Jan 22;40(4):843-851. doi: 10.1523/JNEUROSCI.0564-19.2019. Epub 2019 Nov 20.
- Holbrook AJ, Tustison NJ, Marquez F, Roberts J, Yassa MA, Gillen DL; Alzheimer's Disease Neuroimaging Initiative section sign. Anterolateral entorhinal cortex thickness as a new biomarker for early detection of Alzheimer's disease. Alzheimers Dement (Amst). 2020 Aug 25;12(1):e12068. doi: 10.1002/dad2.12068. eCollection 2020.
- Chappel-Farley MG, Mander BA, Neikrug AB, Stehli A, Nan B, Grill JD, Yassa MA, Benca RM. Symptoms of obstructive sleep apnea are associated with less frequent exercise and worse subjective cognitive function across adulthood. Sleep. 2022 Mar 14;45(3):zsab240. doi: 10.1093/sleep/zsab240.
- Adams JN, Kim S, Rizvi B, Sathishkumar M, Taylor L, Harris AL, Mikhail A, Keator DB, McMillan L, Yassa MA. Entorhinal-Hippocampal Circuit Integrity Is Related to Mnemonic Discrimination and Amyloid-beta Pathology in Older Adults. J Neurosci. 2022 Nov 16;42(46):8742-8753. doi: 10.1523/JNEUROSCI.1165-22.2022. Epub 2022 Oct 27.
- Adams JN, Marquez F, Larson MS, Janecek JT, Miranda BA, Noche JA, Taylor L, Hollearn MK, McMillan L, Keator DB, Head E, Rissman RA, Yassa MA. Differential involvement of hippocampal subfields in the relationship between Alzheimer's pathology and memory interference in older adults. Alzheimers Dement (Amst). 2023 Apr 5;15(2):e12419. doi: 10.1002/dad2.12419. eCollection 2023 Apr-Jun.
Other Study IDs
- BEACoN
- 20173832
- R01AG053555 (U.S. NIH Grant/Contract)
NCT ID Number
Start Date (Actual)
2018-05-01
Last Update Posted
2024-11-01
Completion Date (Estimated)
2027-12-22
Enrollment (Estimated)
300
Study Type
Interventional
PHASE
Phase 3
Status
Recruiting
Keywords
Alzheimer disease
cognitive impairment
mild cognitive impairment
biomarker
MRI
PET
cognitive impairment
mild cognitive impairment
biomarker
MRI
PET
Primary Purpose
Health Services Research
Design Allocation
Non-Randomized
Interventional Model
Parallel
Masking
None (Open Label)
Arms / Interventions
| Participant Group/Arm | Intervention/Treatment |
|---|---|
ExperimentalAge 60-65 ApoE e4+ Participants in this cohort are between the ages of 60-65 and are ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing. | Amyloid PET Scan Amyloid Positron Emission Tomography scan using radio tracer florbetapir-F18 Tau PET Scan Using MK-6240 Tau Positron Emission Tomography scan using radio tracer MK-6240 Neurocognitive Testing A battery of clinical neuropsychological assessments and computerized cognitive tasks will be used to test participants' memory and cognitive abilities. MRI High-resolution structural, functional, and diffusion Magnetic Resonance Imaging scans will be collected during the study. |
ExperimentalAge 66-70 ApoE e4- Participants in this cohort are between the ages of 66-70 and are not ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing. | Amyloid PET Scan Amyloid Positron Emission Tomography scan using radio tracer florbetapir-F18 Tau PET Scan Using MK-6240 Tau Positron Emission Tomography scan using radio tracer MK-6240 Neurocognitive Testing A battery of clinical neuropsychological assessments and computerized cognitive tasks will be used to test participants' memory and cognitive abilities. MRI High-resolution structural, functional, and diffusion Magnetic Resonance Imaging scans will be collected during the study. |
ExperimentalAge 66-70 ApoE e4+ Participants in this cohort are between the ages of 66-70 and are ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing. | Amyloid PET Scan Amyloid Positron Emission Tomography scan using radio tracer florbetapir-F18 Tau PET Scan Using MK-6240 Tau Positron Emission Tomography scan using radio tracer MK-6240 Neurocognitive Testing A battery of clinical neuropsychological assessments and computerized cognitive tasks will be used to test participants' memory and cognitive abilities. MRI High-resolution structural, functional, and diffusion Magnetic Resonance Imaging scans will be collected during the study. |
ExperimentalAge 71-75 ApoE e4- Participants in this cohort are between the ages of 71-75 and are not ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing. | Amyloid PET Scan Amyloid Positron Emission Tomography scan using radio tracer florbetapir-F18 Tau PET Scan Using MK-6240 Tau Positron Emission Tomography scan using radio tracer MK-6240 Neurocognitive Testing A battery of clinical neuropsychological assessments and computerized cognitive tasks will be used to test participants' memory and cognitive abilities. MRI High-resolution structural, functional, and diffusion Magnetic Resonance Imaging scans will be collected during the study. |
ExperimentalAge 71-75 ApoE e4+ Participants in this cohort are between the ages of 71-75 and are ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing. | Amyloid PET Scan Amyloid Positron Emission Tomography scan using radio tracer florbetapir-F18 Tau PET Scan Using MK-6240 Tau Positron Emission Tomography scan using radio tracer MK-6240 Neurocognitive Testing A battery of clinical neuropsychological assessments and computerized cognitive tasks will be used to test participants' memory and cognitive abilities. MRI High-resolution structural, functional, and diffusion Magnetic Resonance Imaging scans will be collected during the study. |
ExperimentalAge 76-80 ApoE e4- Participants in this cohort are between the ages of 76-80 and are not ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing. | Amyloid PET Scan Amyloid Positron Emission Tomography scan using radio tracer florbetapir-F18 Tau PET Scan Using MK-6240 Tau Positron Emission Tomography scan using radio tracer MK-6240 Neurocognitive Testing A battery of clinical neuropsychological assessments and computerized cognitive tasks will be used to test participants' memory and cognitive abilities. MRI High-resolution structural, functional, and diffusion Magnetic Resonance Imaging scans will be collected during the study. |
ExperimentalAge 76-80 ApoE e4+ Participants in this cohort are between the ages of 76-80 and are ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing. | Amyloid PET Scan Amyloid Positron Emission Tomography scan using radio tracer florbetapir-F18 Tau PET Scan Using MK-6240 Tau Positron Emission Tomography scan using radio tracer MK-6240 Neurocognitive Testing A battery of clinical neuropsychological assessments and computerized cognitive tasks will be used to test participants' memory and cognitive abilities. MRI High-resolution structural, functional, and diffusion Magnetic Resonance Imaging scans will be collected during the study. |
ExperimentalAge 81+ ApoE e4- Participants in this cohort are between the ages of 81-85 and are not ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing. | Amyloid PET Scan Amyloid Positron Emission Tomography scan using radio tracer florbetapir-F18 Tau PET Scan Using MK-6240 Tau Positron Emission Tomography scan using radio tracer MK-6240 Neurocognitive Testing A battery of clinical neuropsychological assessments and computerized cognitive tasks will be used to test participants' memory and cognitive abilities. MRI High-resolution structural, functional, and diffusion Magnetic Resonance Imaging scans will be collected during the study. |
ExperimentalAge 81+ ApoE e4+ Participants in this cohort are between the ages of 81-85 and are ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing. | Amyloid PET Scan Amyloid Positron Emission Tomography scan using radio tracer florbetapir-F18 Tau PET Scan Using MK-6240 Tau Positron Emission Tomography scan using radio tracer MK-6240 Neurocognitive Testing A battery of clinical neuropsychological assessments and computerized cognitive tasks will be used to test participants' memory and cognitive abilities. MRI High-resolution structural, functional, and diffusion Magnetic Resonance Imaging scans will be collected during the study. |
Primary Outcome Measures
Secondary Outcome Measures
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
Change in Clinical Dementia Rating - Sum of Box Score | A measure of cognitive/clinical decline | Years 4 and 5 of the grant |
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
Change in lure discrimination index - objects | Key measure of performance on the object pattern separation task | Years 4 and 5 of the grant |
Change in lure discrimination index - spatial | Key measure of performance on the spatial pattern separation task | Years 4 and 5 of the grant |
Change in lure discrimination index - temporal | Key measure of performance on the temporal pattern separation task | Years 4 and 5 of the grant |
Change in entorhinal cortical thickness | Key measure of structural decline on MRI scans | Years 4 and 5 of the grant |
Change in perforant path integrity | Key measure of structural connectivity decline on MRI scans | Years 4 and 5 of the grant |
Change in tau spatial distribution - advancing Braak stage | Key measure of tau spatial spread on tau PET scans | Years 4 and 5 of the grant |
Eligibility Criteria
Eligible Ages
Adult, Older Adult
Minimum Age
60 Years
Eligible Sexes
All
Accepts Healthy Volunteers
Yes
- Aged 60 or older;
- Speaks fluent English or Spanish;
- Visual and auditory acuity adequate for neuropsychological and computerized testing;
- Good general health with no disease(s) expected to interfere with the study;
- Willing and able to participate for the duration of the study and in all study procedures including MRI and PET;
- Normal cognition defined as a Clinical Dementia Rating of 0 and a Mini-Mental State Examination score of 25 or higher. FAST Stage 1 or 2.
- Subjective memory or other cognitive complaints will be included.
- Significant co-morbid neurologic disease such as Parkinson's disease, multiple sclerosis, brain cyst, tumor or aneurysm;
- Major health conditions, except for Type II diabetes mellitus, hypercholesterolemia, and hypertension, which are NOT exclusionary for this study given their high prevalence in our target populations;
- Significant psychiatric disorders such as schizophrenia, bipolar disorder, or attention-deficit hyperactivity disorder, except for depression and anxiety, which are NOT exclusionary for this study given their high prevalence in our target populations;
- Existing diagnosis of dementia or mild cognitive impairment;
- Alcohol or substance abuse or dependence within the past 2 years (DSM-IV criteria);
- MRI contraindications, e.g. pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments or foreign objects in the eyes, skin or body. Females who are pregnant or trying to get pregnant are also excluded;
- PET contraindications, e.g. significant prior radiation exposure and pregnancy.
University of California, Irvine158 active trials to exploreNational Institute on Aging (NIA)Study Responsible Party
Michael Yassa, Principal Investigator, Professor, University of California, Irvine
Study Central Contact
Contact: Evelyn Chang, BA, 949-824-0904, [email protected]
Contact: Novelle Meza, BS, 949-824-5049, [email protected]
1 Study Locations in 1 Countries
California
University of California, Irvine, Irvine, California, 92697, United States
Evelyn Chang, BA, Contact, 949-824-0904, [email protected]
Novelle Meza, BS, Contact, 949-824-5049, [email protected]
Michael A Yassa, PhD, Contact
Recruiting